GEN-MKT-18-7897-A
Jul 14, 2017 | Blogs, Food / Beverage | 0 comments
Don’t judge a nutritional supplement by its label, as often, government monitoring of ingredients begins after the product enters the consumer market1. Meanwhile, there may be additional additives not mentioned on the label as they are used to address supplement side effects. Such is the case in the United States where even though federal law requires supplements to carry a dietary supplement label or a substitutional term, monitoring begins once a supplement is on the market. In China meanwhile, the China Food and Drug Administration’s (CFDA) health product potential illegal additives list, clearly stipulates monitoring processes for additives in six different types of nutritional supplements including weight loss, blood sugar reduction, blood pressure reduction, anti-fatigue, sleep improvement and immune strengthening functions.Read Tech Note >
Keeping up with additives is no small job for the labs tasked with analysis. A research report by Grand View Research notes that “The rising sales of sports nutrition products in the U.S. and China along with new product launches are likely to have a significant impact on the industry. The market is expected to generate revenues worth USD 37.16 billion by 2024.2
Since drug interactions can be unclear, however, they continue to merit clarity. In the following application note, Use of X500R QTOF for Monitoring Unexpected Additives in Nutritional Supplements, researchers used the X500R QTOF high-resolution mass spectrometry and SCIEX OS software for quick and qualitative confirmation of 50 additives. Want to see how your lab can keep up with supplemental screening? Download the tech note to discover how you can overcome matrix interference in complex matrices for the accurate testing of additives such as atenolol, nitrendipine, nifedipine, glibenclamide, glipizide, rosiglitazone, and gliclazide.
The Echo® MS+ system is a novel platform for Acoustic Ejection Mass Spectrometry (AEMS) and combines the speed of acoustic sampling with the selectivity of mass spectrometry. This platform has been designed for high throughput analysis of small and large molecules. The technology combines Acoustic Droplet Ejection (ADE), an Open Port Interface (OPI) and could be coupled with the SCIEX Triple Quad 6500+ system or the ZenoTOF 7600 system.
The Echo® MS+ system comprises of an open-port interface (OPI) and acoustic droplet ejection (ADE) module which could be coupled with a mass spectrometer. The mass spectrometer could either be a SCIEX Triple Quad 6500+ system or the ZenoTOF 7600 system. This non-liquid chromatography based; high-throughput screening platform enables rapid analysis of compounds at speeds of up to 1 sample/second.
The ability to consistently achieve reproducible results on many complex samples across multiple days is critical to a routine clinical laboratory. Laboratories relying on analytical instrumentation require stability and robustness to perform a variety of screening and confirmatory assays with confidence. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has become the preferred analytical method in the clinical laboratory to reliably perform clinical testing as it provides best-in-class performance and reliability for the most challenging assays. LC-MS/MS offers the required levels of sensitivity and specificity for the detection and quantitation of molecules from complex biological samples, helping laboratories deliver highly accurate data for a variety of clinically relevant analytes across a wide range of assays.
Posted by
You must be logged in to post a comment.
Share this post with your network